Studies of anticancer activity in vivo and in vitro behaviors of liposomes encapsulated iridium(III) complex

Gu, Yiying; Wen, Haoyu; Zhang, Yuanyuan; Bai, Lan; Zhou, Yi; Zhang, Huiwen; Tian, Li; Hao, Jing; Liu, Yun-Jun

doi:10.1007/s00775-020-01841-9

Cited by 21 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the synthetic route to this complex, they took a mixture of DQTT and [Ir(piq) 2 Cl] 2 with 45 mL of dichloromethane, and methanol was stirred at 45 °C for 6 h under argon. After cooling, NH 4 PF 6 was added drop by drop and stirred at rt for 2 h. They obtained a pure product with a 75% yield using neutral alumina (Figure ).…”

Section: Discussionmentioning

confidence: 99%

“…The produced liposomes were completely characterized by zeta potential, DLS, and the TEM analytical technique. For the They obtained a pure product with a 75% yield using neutral alumina 25 (Figure 13). An article titled "Phosphorogenic dipyrrinato−iridium(III) complexes as photosensitizers for photodynamic therapy" was published in the same year, 2021, by Ortiz and his colleagues.…”

Section: Acsmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advancement in the Synthesis of Ir-Based Complexes

Joshi,

Shivashankar

2023

ACS Omega

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Acsmentioning

confidence: 99%

Recent Advancement in the Synthesis of Ir-Based Complexes

Joshi,

Shivashankar

2023

ACS Omega

View full text Add to dashboard Cite

“…Liu's group successively reported two cyclometallated iridium (III) complexes 38 and 39 (Figure 3) (Gu et al, 2021;Zhou et al, 2021). Among them, compound 38 exhibited a lower antitumor activity than compound 39.…”

Section: Cyclometalated Iridium (Iii) Complexesmentioning

confidence: 99%

Current status of iridium-based complexes against lung cancer

et al. 2022

View full text Add to dashboard Cite

Lung cancer is one of the most common malignant tumors, with the highest mortality rate in the world, and its incidence is second only to breast cancer. It has posed a serious threat to human health. Cisplatin, a metal-based drug, is one of the most widely used chemotherapeutic agents for the treatment of various cancers. However, its clinical efficacy is seriously limited by numerous side effects and drug resistance. This has led to the exploration and development of other transition metal complexes for the treatment of malignant tumors. In recent years, iridium-based complexes have attracted extensive attention due to their potent anticancer activities, limited side effects, unique antitumor mechanisms, and rich optical properties, and are expected to be potential antitumor drugs. In this review, we summarize the recent progress of iridium complexes against lung cancer and introduce their anti-tumor mechanisms, including apoptosis, cycle arrest, inhibition of lung cancer cell migration, induction of immunogenic cell death, etc.

show abstract

“…In the past 20 years, among these metal complexes, the anticancer activity of Ru (II) complexes has been extensively studied [ 13 , 14 , 15 , 16 , 17 , 18 ]. In recent years, the research in the anticancer activity of iridium (III) complexes has been paid great attention and a number of iridium (III) complexes show potent anticancer efficacy [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Yuan et al reported that two iridium (III) complexes, [Ir(piq) 2 (NPIP)](PF 6 ) (piq = 1-phenylisoquinoline, NPIP = 2-(2-nitrophenyl)-1 H -imidazo[4,5-f][1,10]phenanthroline) and [Ir(bzq) 2 (NPIP)](PF 6 ) (bzq = benzo[ h ]quinolone), targeted the mitochondria and the complexes led to the loss of mitochondrial membrane potential (MMP), increased the intracellular ROS content and further induced apoptosis [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells

Xie

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

In this paper, two new iridium (III) complexes, [Ir(ppy)2(ipbp)](PF6) (Ir1) (ppy = 2-phenylpyridine, ipbp = 3-(1H-imidazo[4,5-f][1,10]phenanthrolin-2yl)-4H-chromen-4-one) and [Ir(bzq)2(ipbp)](PF6) (Ir2) (bzq = benzo[h]quinolone), were synthesized and characterized. The cytotoxicity of the complexes against human colon cancer HCT116 and normal LO2 cells was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The complexes Ir1 and Ir2 show high cytotoxic efficacy toward HCT116 cells with a low IC50 value of 1.75 ± 0.10 and 6.12 ± 0.2 µM. Interestingly, Ir1 only kills cancer cells, not normal LO2 cells (IC50 > 200 µM). The inhibition of cell proliferation and migration were investigated by multiple tumor spheroid (3D) and wound healing experiments. The cellular uptake was explored under a fluorescence microscope. The intracellular reactive oxygen species (ROS), change of mitochondrial membrane potential, glutathione (GSH) and adenine nucleoside triphosphate (ATP) were studied. Apoptosis and cell cycle arrest were performed by flow cytometry. The results show that the complexes induce early apoptosis and inhibit the cell proliferation at the G0/G1 phase. Additionally, the apoptotic mechanism was researched by Western blot analysis. The results obtained demonstrate that the complexes cause apoptosis in HCT116 cells through ROS-mediated mitochondrial dysfunction and the inhibition of PI3K/AKT signaling pathways.

show abstract

Studies of anticancer activity in vivo and in vitro behaviors of liposomes encapsulated iridium(III) complex

Cited by 21 publications

References 61 publications

Recent Advancement in the Synthesis of Ir-Based Complexes

Recent Advancement in the Synthesis of Ir-Based Complexes

Current status of iridium-based complexes against lung cancer

Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells

Contact Info

Product

Resources

About